Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.

November 14, 2018 admin CEO Interview, Healthcare Comments Off

Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company's cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.

This content is available to members only.

If you are an existing member, please LOGIN

Note a member? Sign up for a FREE trial account ($195 per month value), and get immediate access. Free offer expires June 15, 2019.

Register New Account

Free Membership

Log in if you wish to renew an existing subscription.

Username

Email

First Name

Last Name

Password

Password Again

.

Institutional / team access subscriptions, contact Melissa Walters 212-871-2057 ext 2
subscribe@wallstreetreporter.com.

Phunware (NASDAQ: PHUN) Launches Location Experience Kit

September 13, 2019 Comments Off on Phunware (NASDAQ: PHUN) Launches Location Experience Kit
NexTech (OTC: NEXCF) Signs AR eCommerce Deal with Gunwerks

September 13, 2019 Comments Off on NexTech (OTC: NEXCF) Signs AR eCommerce Deal with Gunwerks
Medicine Man Technologies (OTC: MDCL) to Increase Its Manufacturing Efficiencies and Branded Product Offerings with Binding Term Sheet for Canyon LLC

September 12, 2019 Comments Off on Medicine Man Technologies (OTC: MDCL) to Increase Its Manufacturing Efficiencies and Branded Product Offerings with Binding Term Sheet for Canyon LLC
Medicine Man Technologies (OTC: MDCL) Enters into Binding Term Sheet to Acquire Strawberry Fields, an Integrated Operator in Southern Colorado

September 11, 2019 Comments Off on Medicine Man Technologies (OTC: MDCL) Enters into Binding Term Sheet to Acquire Strawberry Fields, an Integrated Operator in Southern Colorado
CytoDyn (OTC: CYDY) Announces FDA Clearance to Proceed with Phase 2 Study of Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer

September 9, 2019 Comments Off on CytoDyn (OTC: CYDY) Announces FDA Clearance to Proceed with Phase 2 Study of Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer
Medicine Man Technologies (OTC: MDCL) to Acquire an Additional Four Dispensaries from an Established Retailer – Largest Transaction in Company History

September 9, 2019 Comments Off on Medicine Man Technologies (OTC: MDCL) to Acquire an Additional Four Dispensaries from an Established Retailer – Largest Transaction in Company History

Register New Account

Related Articles